{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T14:40:02Z","timestamp":1784990402089,"version":"3.55.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,23]],"date-time":"2019-11-23T00:00:00Z","timestamp":1574467200000},"content-version":"am","delay-in-days":387,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K05 DA017918"],"award-info":[{"award-number":["K05 DA017918"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01 DA05018"],"award-info":[{"award-number":["R01 DA05018"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["T32 DA031115"],"award-info":[{"award-number":["T32 DA031115"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["U01 DA034992"],"award-info":[{"award-number":["U01 DA034992"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000928","name":"Welch Foundation","doi-asserted-by":"publisher","award":["AQ-0039"],"award-info":[{"award-number":["AQ-0039"]}],"id":[{"id":"10.13039\/100000928","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.neuropharm.2017.12.023","type":"journal-article","created":{"date-parts":[[2017,12,12]],"date-time":"2017-12-12T03:43:42Z","timestamp":1513050222000},"page":"63-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["The behavioral pharmacology and therapeutic potential of lorcaserin for substance use disorders"],"prefix":"10.1016","volume":"142","author":[{"given":"Gregory T.","family":"Collins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa R.","family":"Gerak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5157-6307","authenticated-orcid":false,"given":"Charles P.","family":"France","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2017.12.023_bib1","series-title":"Briefing Document: NDA 22\u2013529; Lorcaserin Hydrochloride (APD356)","author":"Arena Pharmaceuticals","year":"2010"},{"key":"10.1016\/j.neuropharm.2017.12.023_bib2","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1038\/npp.2016.259","article-title":"Repeated 7-Day treatment with the 5-HT2C agonist lorcaserin or the 5-HT2A antagonist pimavanserin alone or in combination fails to reduce cocaine vs food choice in male rhesus monkeys","volume":"42","author":"Banks","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.12.023_bib3","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/0091-3057(89)90477-2","article-title":"Selective activation of 5HT1A receptors induces lower lip retraction in the rat","volume":"33","author":"Berendsen","year":"1989","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2017.12.023_bib4","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.12.023_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pbb.2015.12.004","article-title":"Dextromethorphan interactions with histaminergic and serotonergic treatments to reduce nicotine self-administration in rats","volume":"142","author":"Briggs","year":"2016","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2017.12.023_bib6","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1124\/jpet.115.228833","article-title":"Lorcaserin reduces the discriminative stimulus and reinforcing effects of cocaine in rhesus monkeys","volume":"356","author":"Collins","year":"2016","journal-title":"JPharmacol Exp Ther"},{"key":"10.1016\/j.neuropharm.2017.12.023_bib7","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000307085","article-title":"Neurophamacology of yawning","volume":"28","author":"Collins","year":"2010","journal-title":"Front Neurol Neurosci"},{"key":"10.1016\/j.neuropharm.2017.12.023_bib8","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.pnpbp.2014.06.004","article-title":"IV nicotine self-administration in rats using a consummatory operant licking response: sensitivity to serotonergic, glutaminergic and histaminergic drugs","volume":"54","author":"Cousins","year":"2014","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.12.023_bib9","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.neuropharm.2011.04.034","article-title":"Selective serotonin 5-HT(2C) receptor activation suppresses the reinforcing efficacy of cocaine and sucrose but differentially affects the incentive-salience value of cocaine- vs. sucrose-associated cues","volume":"61","author":"Cunningham","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2017.12.023_bib10","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1196\/annals.1300.021","article-title":"Glutamatergic agents for cocaine dependence","volume":"1003","author":"Dackis","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2017.12.023_bib11","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/BF00432175","article-title":"Reinstatement of cocaine-reinforced responding in the rat","volume":"75","author":"de Wit","year":"1981","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.12.023_bib12","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s00213-002-1021-6","article-title":"3,4-Methylenedioxymethamphetamine (MDMA, \"ecstasy\") and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement","volume":"161","author":"Fantegrossi","year":"2002","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.12.023_bib13","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1124\/jpet.110.172247","article-title":"Interaction of 5-HT2A and 5-HT2C receptors in R(-)-2,5-dimethoxy-4-iodoamphetamine-elicited head twitch behavior in mice","volume":"335","author":"Fantegrossi","year":"2010","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2017.12.023_bib14","first-page":"576","article-title":"Differential effects of the 5-HT(2A) receptor antagonist M100907 and the 5-HT(2C) receptor antagonist SB242084 on cocaine-induced locomotor activity, cocaine self-administration and cocaine-induced reinstatement of responding","volume":"27","author":"Fletcher","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.12.023_bib15","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/sj.npp.1300319","article-title":"Injection of the 5-HT2C receptor agonist Ro60-0175 into the ventral tegmental area reduces cocaine-induced locomotor activity and cocaine self-administration","volume":"29","author":"Fletcher","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.12.023_bib16","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/sj.npp.1301509","article-title":"The 5-HT2C receptor agonist Ro60-0175 reduces cocaine self-administration and reinstatement induced by the stressor yohimbine, and contextual cues","volume":"33","author":"Fletcher","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.12.023_bib17","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.pbb.2010.07.002","article-title":"Genetic and pharmacological evidence that 5-HT2C receptor activation, but not inhibition, affects motivation to feed under a progressive ratio schedule of reinforcement","volume":"97","author":"Fletcher","year":"2010","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2017.12.023_bib18","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1016\/j.neuropharm.2012.01.023","article-title":"Effects of the 5-HT2C receptor agonist Ro60-0175 and the 5-HT2A receptor antagonist M100907 on nicotine self-administration and reinstatement","volume":"62","author":"Fletcher","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2017.12.023_bib19","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2174\/1874473708666150107121331","article-title":"Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction","volume":"7","author":"Garcia-Romeu","year":"2014","journal-title":"Curr. Drug Abuse Rev."},{"key":"10.1016\/j.neuropharm.2017.12.023_bib20","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1124\/jpet.116.236307","article-title":"Effects of lorcaserin on cocaine and methamphetamine self-administration and reinstatement of responding previously maintained by cocaine in rhesus monkeys","volume":"359","author":"Gerak","year":"2016","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2017.12.023_bib21","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.addbeh.2004.06.018","article-title":"Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence","volume":"29","author":"Grabowski","year":"2004","journal-title":"Addict. Behav."},{"key":"10.1016\/j.neuropharm.2017.12.023_bib22","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0022-3565(24)39021-4","article-title":"Studies to investigate the role of 5-HT(2C) receptors on cocaine- and food-maintained behavior","volume":"295","author":"Grottick","year":"2000","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2017.12.023_bib23","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0896-6273(02)00660-8","article-title":"Altered editing of serotonin 2C receptor pre-mRNA in the prefrontal cortex of depressed suicide victims","volume":"34","author":"Gurevich","year":"2002","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2017.12.023_bib24","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.bbr.2008.03.020","article-title":"Molecular biology of 5-HT receptors","volume":"195","author":"Hannon","year":"2008","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2017.12.023_bib25","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.neuropharm.2015.09.028","article-title":"The 5-HT(2C) receptor agonist lorcaserin reduces cocaine self-administration, reinstatement of cocaine-seeking and cocaine induced locomotor activity","volume":"101","author":"Harvey-Lewis","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2017.12.023_bib26","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/npp.2011.303","article-title":"The 5-HT2C receptor agonist lorcaserin reduces nicotine self-administration, discrimination, and reinstatement: relationship to feeding behavior and impulse control","volume":"37","author":"Higgins","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.12.023_bib27","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.tips.2013.08.001","article-title":"From obesity to substance abuse: therapeutic opportunities for 5-HT2C receptor agonists","volume":"34","author":"Higgins","year":"2013","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2017.12.023_bib28","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00213-012-2919-2","article-title":"Evaluation of chemically diverse 5-HT2C receptor agonists on behaviours motivated by food and nicotine and on side effect profiles","volume":"226","author":"Higgins","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.12.023_bib29","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0022-3565(25)12217-9","article-title":"Serotonergic modulation of the behavioral effects of cocaine in the squirrel monkey","volume":"275","author":"Howell","year":"1995","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2017.12.023_bib30","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1124\/pr.114.009514","article-title":"Serotonin 5-HT2 receptor interactions with dopamine function: implications for therapeutics in cocaine use disorder","volume":"67","author":"Howell","year":"2015","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2017.12.023_bib31","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.pharmthera.2011.03.008","article-title":"Serotonin receptors and heart valve disease\u2013it was meant 2B","volume":"132","author":"Hutcheson","year":"2011","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.neuropharm.2017.12.023_bib32","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/00952990.2016.1170135","article-title":"Long-term follow-up of psilocybin-facilitated smoking cessation","volume":"43","author":"Johnson","year":"2017","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.neuropharm.2017.12.023_bib33","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1177\/0269881116684335","article-title":"An online survey of tobacco smoking cessation associated with naturalistic psychedelic use","volume":"31","author":"Johnson","year":"2017","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.12.023_bib34","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1111\/j.1476-5381.1991.tb12369.x","article-title":"Potencies of antagonists indicate that 5-HT1C receptors mediate 1-3(chlorophenyl)piperazine-induced hypophagia","volume":"103","author":"Kennett","year":"1991","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.12.023_bib35","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0028-3908(97)00038-5","article-title":"SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist","volume":"36","author":"Kennett","year":"1997","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2017.12.023_bib36","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0022-3565(24)36843-0","article-title":"Pharmacological characterization of in\u00a0vivo properties of putative mixed 5-HT1A agonist\/5-HT(2A\/2C) antagonist anxiolytics. II. Drug discrimination and behavioral observation studies in rats","volume":"282","author":"Kleven","year":"1997","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2017.12.023_bib37","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0091-3057(93)90295-5","article-title":"MDL 72222, ketanserin, and methysergide pretreatments fail to alter breaking points on a progressive ratio schedule reinforced by intravenous cocaine","volume":"44","author":"Lacosta","year":"1993","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2017.12.023_bib38","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/nm764","article-title":"Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension","volume":"8","author":"Launay","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2017.12.023_bib39","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1124\/jpet.111.183525","article-title":"Lorcaserin, a 5-HT2C agonist, decreases nicotine self-administration in female rats","volume":"338","author":"Levin","year":"2011","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2017.12.023_bib40","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1124\/jpet.111.186981","article-title":"Effects of serotonin 2C receptor agonists on the behavioral and neurochemical effects of cocaine in squirrel monkeys","volume":"341","author":"Manvich","year":"2012","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2017.12.023_bib41","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1124\/jpet.112.195156","article-title":"The serotonin 2C receptor antagonist SB 242084 exhibits abuse-related effects typical of stimulants in squirrel monkeys","volume":"342","author":"Manvich","year":"2012","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2017.12.023_bib42","first-page":"189","article-title":"Preclinical evaluation of the effects of buprenorphine, naltrexone and desipramine on cocaine self-administration","volume":"105","author":"Mello","year":"1990","journal-title":"NIDA Res. Monogr."},{"key":"10.1016\/j.neuropharm.2017.12.023_bib43","doi-asserted-by":"crossref","first-page":"13367","DOI":"10.1523\/JNEUROSCI.1437-13.2013","article-title":"Serotonin 2A receptors differentially contribute to abuse-related effects of cocaine and cocaine-induced nigrostriatal and mesolimbic dopamine overflow in nonhuman primates","volume":"33","author":"Murnane","year":"2013","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.12.023_bib44","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1021\/acschemneuro.6b00413","article-title":"Lorcaserin suppresses oxycodone self-administration and relapse vulnerability in rats","volume":"8","author":"Neelakantan","year":"2017","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.neuropharm.2017.12.023_bib45","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1038\/npp.2014.322","article-title":"Agonist medications for the treatment of cocaine use disorder","volume":"40","author":"Negus","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.12.023_bib46","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1021\/jm040190e","article-title":"Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents","volume":"48","author":"Newman","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2017.12.023_bib47","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1037\/a0014592","article-title":"Blockade of the serotonin 5-HT2A receptor suppresses cue-evoked reinstatement of cocaine-seeking behavior in a rat self-administration model","volume":"123","author":"Nic Dhonnchadha","year":"2009","journal-title":"Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.12.023_bib48","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.neubiorev.2010.10.012","article-title":"The predictive validity of the rat self-administration model for abuse liability","volume":"35","author":"O'Connor","year":"2011","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2017.12.023_bib49","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00213-010-2071-9","article-title":"Blockade of 5-HT2A receptors in the medial prefrontal cortex attenuates reinstatement of cue-elicited cocaine-seeking behavior in rats","volume":"213","author":"Pockros","year":"2011","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.12.023_bib50","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/sj.bjp.0702751","article-title":"Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells","volume":"128","author":"Porter","year":"1999","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.12.023_bib51","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.pbb.2014.07.017","article-title":"Lorcaserin, a selective 5-HT(2C) receptor agonist, decreases alcohol intake in female alcohol preferring rats","volume":"125","author":"Rezvani","year":"2014","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2017.12.023_bib52","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1126\/science.2820058","article-title":"Cocaine receptors on dopamine transporters are related to self-administration of cocaine","volume":"237","author":"Ritz","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2017.12.023_bib53","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1749-6632.2000.tb06680.x","article-title":"GABA modulation of cocaine self-administration","volume":"909","author":"Roberts","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2017.12.023_bib54","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1517\/14740330902931524","article-title":"Serotonergic drugs and valvular heart disease","volume":"8","author":"Rothman","year":"2009","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.neuropharm.2017.12.023_bib55","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bcp.2007.08.007","article-title":"Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction","volume":"75","author":"Rothman","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.12.023_bib56","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1007\/s00213-015-3932-z","article-title":"Attenuation of cocaine-induced reinstatement of drug seeking in squirrel monkeys by direct and indirect activation of 5-HT2C receptors","volume":"232","author":"R\u00fcedi-Bettschen","year":"2015","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.12.023_bib57","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.pbb.2016.06.002","article-title":"Serotonin antagonists fail to alter MDMA self-administration in rats","volume":"148","author":"Schenk","year":"2016","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2017.12.023_bib58","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.115.228148","article-title":"Directly observable behavioral effects of lorcaserin in rats","volume":"355","author":"Serafine","year":"2015","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2017.12.023_bib59","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/jeab.222","article-title":"Characterization of the discriminative stimulus effects of lorcaserin in rats","volume":"106","author":"Serafine","year":"2016","journal-title":"J.\u00a0Exp. Anal. Behav."},{"issue":"8","key":"10.1016\/j.neuropharm.2017.12.023_bib60","first-page":"944","article-title":"Lorcaserin for smoking cessation and associated weight gain: a randomized 12-week clinical trial","volume":"19","author":"Shanahan","year":"2017","journal-title":"Nicotine Tob. Res."},{"key":"10.1016\/j.neuropharm.2017.12.023_bib61","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/clpt.2011.20","article-title":"Evaluation of the abuse potential of lorcaserin, a serotonin 2C (5-HT2C) receptor agonist, n recreational polydrug users","volume":"89","author":"Shram","year":"2011","journal-title":"Clin. Pharmacol. Therapeut."},{"key":"10.1016\/j.neuropharm.2017.12.023_bib62","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.neuropharm.2006.07.024","article-title":"CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity","volume":"52","author":"Siuciak","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2017.12.023_bib63","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/oby.2008.537","article-title":"Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women","volume":"17","author":"Smith","year":"2009","journal-title":"Obesity"},{"key":"10.1016\/j.neuropharm.2017.12.023_bib64","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJMoa0909809","article-title":"Multicenter, placebo-controlled trial of lorcaserin for weight management","volume":"363","author":"Smith","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2017.12.023_bib65","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S1054-3589(08)57007-4","article-title":"Discovery of drugs to treat cocaine dependence: behavioral and neurochemical effects of atypical dopamine transport inhibitors","volume":"57","author":"Tanda","year":"2009","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.12.023_bib66","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/374542a0","article-title":"Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors","volume":"74","author":"Tecott","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2017.12.023_bib67","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1124\/jpet.107.133348","article-title":"Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in\u00a0vitro and in\u00a0vivo pharmacological characterization","volume":"325","author":"Thomsen","year":"2008","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2017.12.023_bib68","series-title":"World Drug Report 2016","author":"United Nations Office on Drugs and Crime","year":"2016"},{"key":"10.1016\/j.neuropharm.2017.12.023_bib69","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0091-3057(01)00552-4","article-title":"Modulation of 5-HT(2A) receptor-mediated head-twitch behaviour in the rat by 5-HT(2C) receptor agonists","volume":"69","author":"Vickers","year":"2001","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2017.12.023_bib70","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1021\/acschemneuro.5b00017","article-title":"The serotonin 2C receptor agonist lorcaserin attenuates intracranial self-stimulation and blocks the reward-enhancing effects of nicotine","volume":"6","author":"Zeeb","year":"2015","journal-title":"ACS Chem Neurosci"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817306202?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817306202?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T06:52:33Z","timestamp":1758437553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390817306202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":70,"alternative-id":["S0028390817306202"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.12.023","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The behavioral pharmacology and therapeutic potential of lorcaserin for substance use disorders","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.12.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}